ArticleNature2025
Re-adenylation by TENT5A enhances efficacy of SARS-CoV-2 mRNA vaccines.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Aging disrupts transcriptional programs for memory updating in the dorsal hippocampus and reveals a required role forbioRxiv : the preprint server for biology · 2026Article
- The C-terminal region of TENT5 proteins drives ER-associated mRNA polyadenylation via FNDC3 interaction.Cell reports · 2026Article
- mRNA vaccines engage unconventional pathways in CD8Nature · 2026Article
- TENT-5 polyadenylates and regulates male-specific transcripts in Caenorhabditis elegans.G3 (Bethesda, Md.) · 2026Article
- TENT5A Maintains MYC mRNA Stability to Enhance Osteosarcoma Stemness.Cancer research · 2026Article
- RNA-binding proteins and ribonucleoproteins as determinants of immunity.Nature reviews. Immunology · 2026Review
- Hijacking innate immunity to enhance mRNA therapeutics by blocking IFN-P-body-XRN1 axis-mediated degradation.Nature communications · 2026Article
- Degron models: a toolbox for rapid in vivo depletion of essential proteins regulating mRNA metabolism.Communications biology · 2026Article
- CJ-1: an optimized mRNA platform with enhanced protein expression and minimal immunogenicity for therapeutic applications.Gene therapy · 2026Article
- Durability of DNA-LNP and mRNA-LNP vaccine-induced immunity against SARS-CoV-2 XBB.1.5.NPJ vaccines · 2026Article
- Potential Impact of SARS-CoV-2 Spike Protein on HIV-1 Reservoir in People Living with HIV.Viruses · 2026Review
- A dual context-aware basecaller for nanopore direct RNA sequencing.Nature communications · 2026Article
- The mRNA-Based Innovative Strategy: Progress and Challenges.Nano-micro letters · 2026Review
- PolyA tail segmentation improves the stability of the template DNA and increases the translatability of in vitro transcribed mRNA.Nucleic acids research · 2026Article
- Review
- COVID-19 mRNA vaccines: a prospective outlook from technological innovation to clinical practice.Frontiers in immunology · 2026Review
- Advances in linear epitope-based subunit vaccines powered by artificial intelligence: current status and challenges.Frontiers in immunology · 2026Review
- mRNA therapeutics: Transforming medicine through innovation in design, delivery, and disease treatment.Molecular therapy. Nucleic acids · 2025Review
- Article
- Polyadenylation landscape of in vivo long-term potentiation in the rat brain.RNA (New York, N.Y.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Paweł S KrawczykLaboratory of RNA Biology, International Institute of Molecular and Cell Biology, Warsaw, Poland.ORCID 0000-0001-9531-1298
Michał Mazur *Laboratory of RNA Biology, International Institute of Molecular and Cell Biology, Warsaw, Poland.
Wiktoria Orzeł *Laboratory of RNA Biology, International Institute of Molecular and Cell Biology, Warsaw, Poland.ORCID 0000-0003-2639-4944
Olga Gewartowska *Genome Engineering Facility, International Institute of Molecular and Cell Biology, Warsaw, Poland.
Sebastian JeleńLaboratory of RNA Biology, International Institute of Molecular and Cell Biology, Warsaw, Poland.
Wiktor AntczakLaboratory of RNA Biology, International Institute of Molecular and Cell Biology, Warsaw, Poland.ORCID 0000-0003-0019-3896
Karolina KasztelanLaboratory of RNA Biology, International Institute of Molecular and Cell Biology, Warsaw, Poland.ORCID 0000-0002-4524-3044
Aleksandra BrouzeLaboratory of RNA Biology, International Institute of Molecular and Cell Biology, Warsaw, Poland.ORCID 0000-0002-0531-8451
Katarzyna Matylla-KulińskaLaboratory of RNA Biology, International Institute of Molecular and Cell Biology, Warsaw, Poland.
Natalia GumińskaLaboratory of RNA Biology, International Institute of Molecular and Cell Biology, Warsaw, Poland.ORCID 0000-0002-4599-2897
Bartosz TarkowskiLaboratory of RNA Biology, International Institute of Molecular and Cell Biology, Warsaw, Poland.
Ewelina P OwczarekLaboratory of RNA Biology, International Institute of Molecular and Cell Biology, Warsaw, Poland.
Kamila AffekLaboratory of RNA Biology, International Institute of Molecular and Cell Biology, Warsaw, Poland.
Paweł TurowskiExploRNA Therapeutics, Warsaw, Poland.
Agnieszka TudekInstitute of Biochemistry and Biophysics, Warsaw, Poland.ORCID 0000-0002-6085-1072
Małgorzata SrokaLaboratory of Protein Structure, International Institute of Molecular and Cell Biology, Warsaw, Poland.
Tomasz ŚpiewlaFaculty of Physics, University of Warsaw, Warsaw, Poland.ORCID 0000-0002-6542-3966
Monika Kusio-KobiałkaLaboratory of RNA Biology, International Institute of Molecular and Cell Biology, Warsaw, Poland.
Aleksandra WesołowskaDepartment of Medical Biology, Medical University of Warsaw, Warsaw, Poland.
Dominika NowisLaboratory of Experimental Medicine, Medical University of Warsaw, Warsaw, Poland.ORCID 0000-0003-2748-9523
Jakub GolabDepartment of Immunology, Medical University of Warsaw, Warsaw, Poland.
Joanna KowalskaFaculty of Physics, University of Warsaw, Warsaw, Poland.ORCID 0000-0002-9174-7999
Jacek JemielityCentre of New Technologies, University of Warsaw, Warsaw, Poland.ORCID 0000-0001-7633-788X
Andrzej DziembowskiLaboratory of RNA Biology, International Institute of Molecular and Cell Biology, Warsaw, Poland. adziembowski@iimcb.gov.pl.ORCID 0000-0001-8492-7572
Seweryn MroczekLaboratory of RNA Biology, International Institute of Molecular and Cell Biology, Warsaw, Poland. s.mroczek2@uw.edu.pl.ORCID 0000-0001-5026-1741
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the widespread use of mRNA vaccines against COVID-19, little is known about the metabolism of therapeutic RNAs. Here we use nanopore sequencing
Indexed as
COVID-19COVID-19 VaccinesPoly ARNA, MessengerSARS-CoV-2Vaccine Efficacy2019-nCoV Vaccine mRNA-1273AnimalsBNT162 VaccineFemaleHumansMicemRNA VaccinesPolyadenylationRNA Stability2019-nCoV Vaccine mRNA-1273BNT162 VaccineCOVID-19 VaccinesmRNA VaccinesPoly ARNA, Messenger
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.